According to the American Cancer Association, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.
Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(R) 500 ultrasound device to destroy cancerous tissue with focused sound waves.
For more and more information regarding the risks and benefits associated with HIFU, go to www.InternationalHIFU.com.
Produced for International HIFU